Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) has provided an update.
Imugene announced that new data from its lead CAR T program, azer-cel, has been selected for an oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, the world’s premier oncology conference. The competitive selection, from more than 8,500 reviewed abstracts, underscores the perceived clinical merit of azer-cel and highlights Imugene’s growing profile in next-generation cell therapies, with further presentation details and full data to be made public in line with ASCO’s abstract release schedule.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company developing novel immunotherapies that activate the immune system to treat and eradicate tumors. Its pipeline spans off-the-shelf allogeneic CAR T cell therapy azer-cel targeting CD19 in blood cancers and oncolytic virotherapy platforms designed to be used alongside standard-of-care drugs and emerging immunotherapies, with the goal of establishing foundation cancer treatments in a rapidly growing global market.
Average Trading Volume: 1,671,394
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$49.98M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.